Chap121N Castration-Resistant Prostate Cancer

• Androgen ablation induces apoptosis. 
• Docetaxel is the first-line chemotherapeutic agent for metastatic castrationresistant
• prostate cancer.

Sipuleucel-T is a treatment option for patients with minimally or asymptomatic metastatic prostate cancer. Treatment is generally very safe. There is no evidence that sipuleucel-T treatment causes symptomatic relief, any clinically meaningful PSA declines, or delay in disease progression. The drug was approved based on a survival benefit compared with placeb

Testosterone levels < 50 ng/mL,before diagnosing castration resistant PCa.